https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-08-08 / Front Immunol 2019;10:1832
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-08-08 / Front Immunol 2019;10:18322019-08-08 00:00:002019-08-08 00:00:00A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-19 / Oncology 2019 Jun;:1-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-19 / Oncology 2019 Jun;:1-142019-06-19 00:00:002019-06-19 00:00:00Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)2019-05-31 00:00:002020-05-06 15:03:38Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)2019-05-31 00:00:002019-05-31 00:00:00Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-27 / Trials 2019 Apr;20(1):242
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-27 / Trials 2019 Apr;20(1):2422019-04-27 00:00:002021-05-19 15:22:19A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-11-28 / Cancers (Basel) 2018 Nov;10(12)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-11-28 / Cancers (Basel) 2018 Nov;10(12)2018-11-28 00:00:002019-03-27 10:44:23Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-4062018-10-12 00:00:002019-03-25 10:39:48Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-26 / Cancers (Basel) 2018 Sep;10(10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-26 / Cancers (Basel) 2018 Sep;10(10)2018-09-26 00:00:002018-09-26 00:00:00The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-18 / Oncol Lett 2018 Nov;16(5):6742-6748
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-18 / Oncol Lett 2018 Nov;16(5):6742-67482018-09-18 00:00:002019-03-27 10:59:42Hyperthermia enhances the sensitivity of pancreatic cancer SW1990 cells to gemcitabine through ROS/JNK signaling
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-18 / Cancer Cell Int. 2018;18:85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-18 / Cancer Cell Int. 2018;18:852018-06-18 00:00:002019-02-15 08:46:17Targeting dendritic cells in pancreatic ductal adenocarcinoma
